MedTrace Logo

Study to Evaluate a HIV Drug for the Treatment of HIV Infection

NCT01803074 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2019-11-25

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to study the safety and tolerability of a HIV drug and to evaluate a decrease of HIV-1 virus level in blood after treatments in HIV-1 infected patients

Conditions

  • Infection, Human Immunodeficiency Virus
  • HIV Infections

Interventions

DRUG

BMS-955176

BMS-955176

DRUG

Placebo matching with BMS-955176

Placebo matching with BMS-955176

DRUG

Atazanavir

Atazanavir

DRUG

Ritonavir

Ritonavir

DRUG

Tenofovir

Tenofovir

DRUG

Emtricitabine

Emtricitabine

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · ViiV Healthcare

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-04
Primary Completion
2014-11-29
Completion
2014-11-29

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01803074 on ClinicalTrials.gov